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Altered copper homeostasis and hypercholesterolemia have been identified independently
as risk factors for Alzheimer’s disease (AD). Abnormal copper and cholesterol metabolism
are implicated in the genesis of amyloid plaques and neurofibrillary tangles (NFT), which
are two key pathological signatures of AD. Amyloidogenic processing of a sub-population
of amyloid precursor protein (APP) that produces Aβ occurs in cholesterol-rich lipid rafts
in copper deficient AD brains. Co-localization of Aβ and a paradoxical high concentration
of copper in lipid rafts fosters the formation of neurotoxic Aβ:copper complexes. These
complexes can catalytically oxidize cholesterol to generate H2O2, oxysterols and other
lipid peroxidation products that accumulate in brains of AD cases and transgenic mouse
models. Tau, the core protein component of NFTs, is sensitive to interactions with
copper and cholesterol, which trigger a cascade of hyperphosphorylation and aggregation
preceding the generation of NFTs. Here we present an overview of copper and cholesterol
metabolism in the brain, and how their integrated failure contributes to development
of AD.
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INTRODUCTION
Since the first case description of Alzheimer’s disease (AD) by
Alois Alzheimer, AD has steadily gained increasing recognition
as the most common neurodegenerative disorder worldwide, and
as such, it has been the focus of intense biomedical research
efforts. The main brain regions affected in AD include the
enterohinal cortex, hippocampus, basal forebrain and amygdala,
which exhibit synaptic loss resulting in extensive brain atrophy
(Mattson, 2004). Currently, confirmation of an AD diagnosis
requires post-mortem examination of the brain for the presence
of extracellular amyloid plaques and intracellular neurofibrillary
tangles (NFTs) (Alzheimer, 1907), which are the key identify-
ing pathological signatures of AD. Clinically, AD patients present
with symptoms of memory loss, altered personality and behav-
ior, and impaired executive function. Medical advances that have
contributed to increased longevity and an aging world popula-
tion is propelling the number of AD cases on a trajectory to
quadruple to 106.2 million over the next 40 years (Brookmeyer
et al., 2007). This is projected to lead to an ∼500% increase
in medical and health care costs (http://www.alz.org). In addi-
tion, AD can cost patients’ family and friends their physical and
emotional health, as well as significant financial loss. Therefore,
there is a huge demand for an effective disease-modifying ther-
apy for AD that will extend the productive and healthy lifetime
of individuals, and reduce its negative socio-economic impact on
society.
AD cases can be broadly classified as familial or sporadic.
Early-onset familial AD (FAD), which comprises 5–10% of AD
cases, is caused by genetic mutations in the genes encoding
the amyloid precursor protein (APP) and presenilins 1 and 2
(PSEN1 and PSEN2). The remaining AD cases are late-onset
and sporadic, with diverse biochemical and clinical presenta-
tions. Common to both types of AD is the increased level of
Aβ peptide, especially the neurotoxic Aβ42 species, as a con-
sequence of enhanced cleavage of APP by β- and γ-secretases.
The complex and multifactorial biochemistry that underlies spo-
radic AD presents a challenge to the discovery of a specific
etiology and hence the development of an effective univer-
sally applicable therapy. Aging is acknowledged as the leading
risk factor for AD, with numerous genetic and environmen-
tal factors also found to associate with AD (Pappolla et al.,
2003; Cannon and Greenamyre, 2011; Hollingworth et al., 2011;
Naj et al., 2011; Bertram and Tanzi, 2012). However, detailed
understanding of the contribution of most of these risk fac-
tors to the etiology of sporadic AD is yet to be achieved.
Amongst the various risk factors for AD, corrupted copper and
cholesterol homeostasis have attracted considerable attention
independently over the last two decades as potential therapeu-
tic targets. Both copper and cholesterol are critical to normal
brain development and function, which include neurotrans-
mission, myelination, and synaptogenesis. Mounting evidence
indicates a connection between copper and cholesterol path-
ways in the pathogenesis of AD. Here we present an overview
of copper and cholesterol metabolism in the brain, and the
first description of how their integrated failure may lead to the
development of AD.
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BRAIN COPPER HOMEOSTASIS
There is an increasing appreciation of a role for copper in
normal brain development and function. The importance of
copper for normal brain function is underscored by the pro-
found neurodegeneration in Menkes and Wilson diseases, rare
genetic disorders of copper deficiency and overload, respectively
(Burkhead et al., 2011; Kaler, 2011). More commonly, copper
dyshomeostasis is evident in a number of major neurodegener-
ative disorders, which include AD and Parkinson’s disease (PD).
Compromised copper regulation in these disorders potentiates
inappropriate interactions with aggregation-prone proteins such
as Aβ and α-synuclein, respectively, to form neurotoxic copper-
protein aggregates (Atwood et al., 1998, 2004; Drew et al., 2008;
Gunn et al., 2012; Camponeschi et al., 2013).
The estimated copper content in a healthy human adult
brain is 7–10% of total body copper, similar to that found in
the liver, the major organ of copper homeostasis (Cartwright
and Wintrobe, 1964; Linder, 1991). The redox cycling of cop-
per between Cu2+ and Cu+ oxidation states is exploited by
many metabolic processes to catalyze various enzyme reactions.
Some of the key cuproenzymes include ceruloplasmin (CP;
iron transport and radical scavenging), Cu,Zn-superoxide dis-
mutase 1 (SOD1; antioxidant defense), dopamine-β-hydroxylase
(neurotransmission), cytochrome c oxidase (CCO; electron
transport and oxidative phosphorylation), and tyrosinase (pig-
mentation) [reviewed in (Linder and Hazegh-Azam, 1996; Nevitt
et al., 2012)]. Paradoxically, the utilization of copper’s redox
activity in Fenton or Haber–Weiss reactions promotes the pro-
duction of toxic reactive oxygen species (ROS) (Halliwell and
Gutteridge, 1984). Oxidative stress, such as that evident in AD,
ensues when the production of ROS overwhelms available antiox-
idant defenses. The brain is particularly vulnerable to oxidative
stress with disproportionately low levels of antioxidants relative
to its high rate of oxidative metabolism (Floyd, 1999). Therefore,
the dichotomous nature of copper demands a precise regula-
tion to maintain an appropriate level and distribution in the
brain, and to prevent inadvertent interactions with other cellular
components.
In a human adult brain, copper is particularly enriched in the
hippocampus (Dobrowolska et al., 2008) and substantia nigra
(Davies et al., 2013). In the hippocampus, following neuronal
depolarization, about 15μM of copper is released into the gluta-
matergic synaptic cleft from synaptic vesicles (Rajan et al., 1976;
Hartter and Barnea, 1988; Kardos et al., 1989; Barnea et al.,
1990; Hopt et al., 2003). This release of copper during neu-
rotransmission involves copper-independent trafficking of the
copper transporter ATP7A to neuronal processes after glutamate
excitation of synaptic N-methyl-D-aspartate (NMDA) receptors
(Schlief et al., 2005, 2006). This ATP7A-mediated copper release
has been proposed to be a neuroprotective mechanism, whereby
synaptic copper catalyzes S-nitrosylation of NMDA receptors to
down-regulate their activity, and thus protects neurons from
excitotoxicity (Schlief et al., 2006). The ability of copper to medi-
ate suppression of long-term potentiation (LTP) in hippocampal
slices further supports a role for copper as a neuromodulator
(Doreulee et al., 1997). In contrast to a role for copper in hip-
pocampal glutamatergic synapse neurotransmission, the role of
copper in the substantia nigra remains obscure. In the sub-
stantia nigra, there is a concomitant elevation of copper, iron
and zinc compared to other brain regions (Davies et al., 2013).
The substantia nigra is therefore, more susceptible to oxida-
tive stress that can be induced by redox-active copper and iron.
Paradoxically, greater concentration of copper and zinc is likely
to be associated with a higher demand for copper- and zinc-
dependent antioxidant activity of SOD1 in the substantia nigra
to counter oxidative stress (Saggu et al., 1989; Davies et al.,
2013).
BRAIN COPPER IMPORT AND EXPORT
Copper is generally acquired through dietary intake of copper-
rich foods such as animal liver, nuts, and shellfish. Dietary copper
(Cu2+) is absorbed into the body by intestinal mucosal cells, and
delivered to the liver via the portal blood bound to albumin, tran-
scuprein, amino acids, and small peptides (Bearn and Kunkel,
1954; Neumann and Sass-Kortsak, 1967; Weiss and Linder, 1985;
Wirth and Linder, 1985). In hepatic cells, copper is incorporated
into CP, which carries the majority of copper in the blood for cir-
culation to extrahepatic tissues (Campbell et al., 1981; Lee et al.,
1993). Excess dietary copper is secreted into the bile from hepatic
cells via biliary canaliculi and eliminated in feces.
Emerging studies of brain copper homeostasis is beginning
to shed light on the mechanism of brain copper import, distri-
bution and export. A concentration difference of up to 100-fold
between plasma (11–25μM) (Tietz, 1987) and cerebrospinal fluid
(CSF; ∼0.25μM) copper signifies restricted copper uptake into
the brain (Kjellin, 1963; Lentner, 1981). A rat brain perfusion
study suggested that non-protein bound free copper ion is the
predominant copper species that enters the brain via both the
blood-brain barrier (BBB) and the blood-cerebrospinal fluid bar-
rier (BCB) (Choi and Zheng, 2009). The greater uptake of copper
into the brain parenchyma compared to CSF suggests that the
BBB is the main site through which copper enters the brain. An
enrichment of copper transporters CTR1, ATP7A, and ATP7B in
the brain capillaries and choroid plexus, implicates their involve-
ment in controlling copper influx into the brain parenchyma and
CSF (Iwase et al., 1996; Qian et al., 1998; Kuo et al., 2006; Niciu
et al., 2006; Choi and Zheng, 2009; Donsante et al., 2010; Davies
et al., 2013).
The high affinity copper transporter CTR1 is the primary
gatekeeper of copper entry into the brain via brain capillary
endothelial cells that form the BBB and choroid plexus epithe-
lial cells that form the BCB. Consistent with a role for CTR1 in
cellular copper uptake, it is localized predominantly at the api-
cal membrane in human choroid plexus epithelial cells (Davies
et al., 2013). Furthermore, CTR1 heterozygous mice have lower
brain copper concentration relative to wild-type controls, and
copper deficiency induces an up-regulation of choroid plexus
CTR1 expression in mice (Kuo et al., 2001, 2006; Lee et al.,
2001; Gybina and Prohaska, 2006). An alternate route of cop-
per uptake into the brain is via the divalent metal transporter,
DMT1 (Arredondo et al., 2003). However, the extent to which
DMT1 participates in brain copper import is unclear, particu-
larly in the wake of a recent study disputing copper transport by
DMT1 (Illing et al., 2012). In conjunction with CTR1, ATP7A,
Frontiers in Physiology | Membrane Physiology and Biophysics May 2013 | Volume 4 | Article 111 | 2
Hung et al. Copper, cholesterol, and Alzheimer’s disease
and ATP7B regulate the rate-limiting step of copper influx into
the brain. Immunohistochemical stains revealed that in choroid
plexus epithelial cells, ATP7A predominantly localizes to the
basolateral membrane, whereas ATP7B localizes to the apical
membrane (Davies et al., 2013). The distinct membrane local-
ization of these two homologous copper transporters may be a
regulatory mechanism related to their respective enzyme kinet-
ics to provide a strict control over copper transport across the
BCB and BBB (Tsivkovskii et al., 2002; Barnes et al., 2005; Hung
et al., 2007). The comparatively slower rate of copper movement
into the CSF relative to copper influx into choroid plexus may be
explained by the presence of kinetically slower ATP7B at the CSF-
facing apical membrane of choroid plexus epithelial cells (Choi
and Zheng, 2009). The kinetically faster ATP7A is more favorably
localized to the basolateral membrane to facilitate copper efflux
into the blood (Davies et al., 2013). Therefore, BCB serves as the
main exit route for excess copper from the brain. Conversely, BBB
as themain entry point for copper into the brain has lower ATP7A
expression with a brain capillary-facing basolateral localization to
enable rapid but limited import of copper into the brain to coun-
terbalance any sudden brain copper depletion (Choi and Zheng,
2009).
INTRACELLULAR COPPER TRANSPORT IN BRAIN CELLS
There have been limited studies on brain cellular copper trans-
port. It has been largely assumed that the homeostatic mech-
anisms that regulate cellular copper movement in brain cells
parallel that of well-defined pathways in peripheral cells. Indeed,
recent studies in astrocytes support this notion (Scheiber et al.,
2010, 2012). CTR1, in addition to mediating the initial copper
uptake into the brain, is implicated also in general copper uptake
into neuronal and glial cells. However, differential expression
of CTR1 in different brain cells pertains to cell-specific copper
requirements (Davies et al., 2013).
To prevent the generation of ROS by free copper ions inside
cells, three well-characterized metallochaperone pathways have
evolved to escort intracellular copper: (1) ATOX1; (2) CCS; and
(3) COX17. The copper chaperone ATOX1 is widely expressed
in the brain, which include the hippocampus, thalamus, cerebel-
lum, and corpus callosum (Klomp et al., 1997; Naeve et al., 1999;
Davies et al., 2013). It delivers copper to cuproenzymes in the
secretory pathway, and in particular, to the copper transporters
ATP7A and ATP7B at the trans-Golgi network (TGN). In addi-
tion to its role as a copper chaperone, it regulates the catalytic
activity of ATP7B (Walker et al., 2002). ATOX1 is essential to
ATP7A copper efflux activity. It stimulates ATP7A translocation
from the TGN to the cell surface via direct interactions and cop-
per exchange (Hamza et al., 2003). Consistent with the original
identification of ATOX1 in the yeast Saccaromyces cerevisae as an
antioxidant protein (Lin and Culotta, 1995), its over-expression
in neuronal cell lines confers protection against oxidative insults
(Kelner et al., 2000).
The copper chaperone for superoxide dismutase (CCS) loads
copper into SOD1 located in the cytoplasm (Culotta et al., 1997).
It is expressed in the mammalian brain, but its expression relative
to brain regional distribution is unknown (Gybina and Prohaska,
2006). Interestingly, the expression of CCS is sensitive to copper
deficiency in the cerebellum, but not in the choroid plexus
(Gybina and Prohaska, 2006). In addition to its interactions with
SOD1, CCS also transports copper to BACE1 (Angeletti et al.,
2005), the β-secretase involved in APP cleavage that results in
the production of amyloid plaque-forming Aβ peptide. CCS defi-
ciency promotes Aβ production, which implicates CCS in the
regulation of BACE1 activity (Gray et al., 2010). Furthermore,
BACE1 competes with SOD1 for binding to CCS, which may con-
tribute to oxidative stress evident in AD (Angeletti et al., 2005;
Dingwall, 2007).
COX 17 is the copper chaperone responsible for delivery of
copper to COX11, SCO1, and SCO2 in the mitochondria for the
metallation of CCO (Glerum et al., 1996a,b; Amaravadi et al.,
1997; Beers et al., 1997; Horvath et al., 2000; Horng et al., 2004).
It is highly expressed in the cerebral cortex, cerebellum and brain
stem, with low expression in the hippocampus and hypothalamus
(Kako et al., 2000).
In addition to the metallochaperone-mediated intracellular
copper transport, copper can bind also to glutathione (GSH)
for transfer to cystein-rich metallothioneins (MT) for storage
(Freedman et al., 1989). Notably, astrocyte secretion of MT3 into
the synaptic cleft regulates the availability of copper ions released
during neurotransmission (Uchida et al., 2002), and confers neu-
roprotection by removal of copper from redox-active Aβ:Cu2+
complexes abundant in AD brains (Meloni et al., 2008). The
importance of GSH in neuronal copper homeostasis is high-
lighted by the exquisite sensitivity of cultured primary cortical
neurons to trace amounts of extracellular copper after GSH deple-
tion. The neurotoxic effect is postulated to involve the generation
of Cu+ and ensuing free radical mediated oxidative stress (White
et al., 1999a; White and Cappai, 2003).
Intracellular copper concentration is further maintained by
the export of excess copper via P-type ATPases ATP7A and
ATP7B. In the brain, the expression and distribution of ATP7A
and ATP7B are developmentally regulated (Barnes et al., 2005;
El Meskini et al., 2005; Niciu et al., 2006). In an adult brain,
their expression is particularly abundant in neurons from copper-
rich brain regions such as the hippocampus, olfactory bulb,
cerebellum and choroid plexus (Iwase et al., 1996; Saito et al.,
1999; Barnes et al., 2005; Niciu et al., 2006; Choi and Zheng,
2009; Davies et al., 2013). Notably, the co-enrichment of copper
and ATP7A in the hippocampus highlights their critical par-
ticipation in neurotransmission, and potential involvement in
learning and memory. Low levels of ATP7A are present also in
a sub-population of astrocytes, microglia, myelinating oligoden-
drocytes, tanycytes, and endothelial cells (Niciu et al., 2006). In
the rodent cerebellum, ATP7A and ATP7B are reported to have
a distinct cell and developmental specific expression. ATP7B is
expressed constitutively in Purkinje neurons, where it functions
to deliver copper to CP; whereas there is a developmental shift in
ATP7A expression from the Purkinje neurons to Bergmann glia
(Barnes et al., 2005). However, in the post-mortem human adult
brain, both ATP7A and ATP7B are strongly expressed in Purkinje
neurons, but not in Bergmann glia (Davies et al., 2013). At a
cellular level, ATP7A, and ATP7B are localized at the TGN, and
undergo copper-responsive redistribution to the basolateral and
apical cell surface, respectively, where they mediate copper efflux
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(Niciu et al., 2006; Davies et al., 2013). Additionally, ATP7A local-
izes to the axon in maturing olfactory receptor neurons, where it
has a putative role in axonal outgrowth and synaptogenesis (El
Meskini et al., 2005, 2007).
BRAIN CHOLESTEROL HOMEOSTASIS
Cholesterol is a fundamental component of the brain. It is an
integral structural constituent of cellular membranes of all body
cells and a precursor of a number of sterols, hormones, and vita-
mins. Perturbed brain cholesterol balance can affect membrane
dynamics and stability, and contributes to neuronal degenera-
tion, loss of synaptic plasticity and neurotransmission (Koudinov
and Koudinova, 2001, 2005). Indeed, neurons may require a
threshold level of cholesterol synthesis as statin treatment reduced
synapse density and impaired synaptic vesicle release from hip-
pocampal neurons (Mailman et al., 2011). Therefore, it is vital for
synaptogenesis, dendritogenesis, axonal guidance, and brain cell
signaling events (Mauch et al., 2001; Hering et al., 2003; Goritz
et al., 2005; Ko et al., 2005; Guirland and Zheng, 2007; Stottmann
et al., 2011). Furthermore, the importance of cholesterol to nor-
mal brain development, structure and function is exemplified
in neurodegenerative disorders such as Niemann-Pick type C
(NP-C) disease, Tangier disease, Smith-Lemi-Opitz Syndrome,
Huntington’s disease, PD, and AD, that are associated with either
genetic or regulatory defects in cholesterol metabolic pathways.
The brain has a disproportionately high cholesterol content
to total body mass ratio. The human brain is ∼2% of total
body mass, yet it contains about a quarter of total body choles-
terol. Almost the entire pool of brain cholesterol (>99.5%) is
present in the unesterified form, with a distribution rank order
of myelin (70%) > glia (20%) > neurons (10%) [reviewed in
Björkhem and Meaney (2004) and Dietschy and Turley (2004)].
Brain cholesterol represents a distinct pool from that in the
peripheral circulation, which is efficiently segregated by the BBB.
Experimental evidence, using 14C- or 2H-labeled cholesterol,
demonstrated that there is negligible exchange of cholesterol
between the brain and plasma. In animal models with an intact
BBB, uptake of dietary 2H-labeled cholesterol into the brain is less
than 1% (Meaney et al., 2000). Moreover, in terminally ill human
patients with potentially compromised BBB, the detectable influx
of 14C-labeled cholesterol from peripheral circulation was negli-
gible (Chobanian andHollander, 1962). Thus, the primary source
of brain cholesterol is de novo synthesis in both neuronal and
glial cells, via the mevalonate pathway, mainly in the endoplas-
mic reticulum (ER) [reviewed in Buhaescu and Izzedine (2007)
and Goldstein and Brown (1990)].
BRAIN CHOLESTEROL SYNTHESIS
The rate of brain cholesterol synthesis is developmentally reg-
ulated. The highest rate of cholesterol synthesis occurs during
the early postnatal period and early life, a critical time for brain
development (Zhang et al., 1996; Dietschy and Turley, 2004). The
primary site of cholesterol synthesis is in cholesterol-rich oligo-
dendrocytes that form the insulatingmyelin sheath around axons.
High levels of cholesterol in myelin is required to increase axonal
electrical resistance but decrease the capacitance of the surround-
ing plasmamembrane, effectively acting as a barrier to dissipation
of electrical impulses across the membrane, whilst promoting
transmission down the axon (Snipes and Suter, 1997; Saher et al.,
2005). Thus, cholesterol and myelination are essential to neuro-
transmission that can influence cognitive and motor activities.
Therefore, it is no coincidence that the most productive period
of myelination parallels that of cholesterol synthesis (Saher et al.,
2005). The impact of cholesterol-deficiency and hypomyelination
on brain development is evident in neurodegenerative disorders
of cholesterol metabolism such as Smith-Lemi-Opitz Syndrome,
cerebrotendinous xanthomatosis, hereditary spastic paresis type
SPG5, and NP-C, which present clinical symptoms that include
mental retardation, dementia, and ataxia [reviewed in Björkhem
et al. (2010) and Ikonen (2006)].
The rate of brain cholesterol synthesis declines with brainmat-
uration and age. To preserve a constant level of cholesterol, it
has been postulated that in the adult brain, cholesterol is effi-
ciently recycled. Daily sterol turnover in both mouse and human
brains is about 20-fold lower compared with that in whole body
(Dietschy and Turley, 2004). The estimated half-life of cholesterol
in rat brains is about four to six months (Andersson et al., 1990;
Björkhem et al., 1997), and in human brains, is estimated to be
5 years (Björkhem et al., 1998). In comparison, in the periph-
ery, the half-life of rat hepatic cholesterol is only about 4 days
(Andersson et al., 1990) and 14C-labeled cholesterol in human
plasma has a reported half-life of about 6 days (Bekersky et al.,
2001).
In the adult brain, cholesterol synthesis is not limited to oligo-
dendrocytes, the major center of brain cholesterol production.
Attenuated cholesterol synthesis occurs in neurons and astro-
cytes, but the extent of endogenous cholesterol production in
these cells is poorly understood. It has been proposed that in
the post-developmental period, it is more energetically efficient
for neurons to minimize cholesterol production in favor of elec-
trical impulse propagation that is vital to neurotransmission;
and to satisfy neuronal cholesterol requirements, cholesterol is
imported from glial cells (Pfrieger, 2003). This hypothesis is sup-
ported by experiments involving in vivo neuronal conditional
inactivation of squalene synthase, the rate-limiting enzyme in
the cholesterol synthesis pathways dedicated to sterol formation
(Fünfschilling et al., 2007, 2012). Neighboring astrocytes rescued
defects in neuronal projection caused by the enforced neuronal
cholesterol deficiency. In contrast, the mouse embryonic brain
showed a greater demand for cholesterol and it is highly sensitive
to cholesterol deficiency. Exogenous cholesterol imported from
microglia only partially compensated for the embryonic neu-
ronal cholesterol deficit. Consequently, themouse pups were born
with extensive neuronal degeneration at birth (Fünfschilling et al.,
2012). Nevertheless, these observations do not preclude endoge-
nous cholesterol synthesis in neurons. In the adult mouse brain
cortical, hippocampal and cholinergic neurons, high expression
of key enzymes involved in the first and last step of choles-
terol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase (HMG-CoA reductase) and 7-dehydrocholesterol reductase
(DHCR7), respectively, suggest cholesterol synthesis occurs in
these neurons (Korade et al., 2007). At present, the require-
ment for endogenous cholesterol production in these neurons is
unclear.
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BRAIN CHOLESTEROL TRANSPORT: ApoE
The inter- and intra-cellular transfer of cholesterol in the brain
involves a multitude of apolipoproteins, lipoprotein receptors and
lipid transporters. Apolipoprotein E (ApoE), a 299-amino acid
glycoprotein, is the primary apolipoprotein involved in the regu-
lation of lipid transport in both the plasma and the CSF [reviewed
in Hauser et al. (2011), Holtzman et al. (2012) and Leduc et al.
(2010)]. In humans, there are three major ApoE isoforms: E2, E3,
and E4, encoded by polymorphic APOE alleles ε2, ε3, ε4, respec-
tively. These isoforms are distinguished by their combination of
cysteine and arginine residues at amino acid positions 112 and
158. ApoE3 with the highest allelic frequency (50–90%) is gen-
erally considered to be the “parental” form with C112 and R158,
whereas in ApoE2, both of these amino acid residues are cysteines,
and in ApoE4, both are arginines (Utermann et al., 1984; Mahley,
1988). In contrast, only an ApoE3-equivalent form of ApoE is
present in all other species (Hatters et al., 2006). The APOE-ε4
genotype is the strongest known genetic risk factor for sporadic
late-onset AD (Mahley, 1988; Bertram and Tanzi, 2012). Hence,
ApoE is the best characterized of all known apolipoproteins,
which include ApoA-I, ApoD, and ApoJ (clusterin) (Borghini
et al., 1995). Of these other apolipoproteins, ApoJ has gained
increasing research interest in recent years with its emergence
as another key genetic risk factor for AD from genome-wide
association studies (Bertram and Tanzi, 2009; Harold et al., 2009).
Similar to cholesterol, ApoE in the brain derives primar-
ily from de novo synthesis in glial cells, mostly in astrocytes
(Boyles et al., 1985; Pitas et al., 1987a), and there is effectively no
exchange with ApoE from the plasma due to lack of permeability
through the BBB under normal conditions (Linton et al., 1991).
Paradoxically, the stability of the BBB requires ApoE, which exerts
an isoform-dependent influence on the integrity of cerebrovascu-
lature (Methia et al., 2001; Nishitsuji et al., 2011; Bell et al., 2012).
Minor amounts of ApoE are produced in neurons and microglia
under normal conditions, but selective up-regulation of neuronal
ApoE can occur under pathological conditions such as stroke and
AD (Xu et al., 1999; Aoki et al., 2003). The functional importance
of neuronal ApoE under such conditions is not well understood,
but indicates a potential role for neuron-derived ApoE to enhance
local cholesterol recycling to facilitate neuronal repair.
Astrocyte-derived ApoE has a dual role in cholesterol trans-
port. It is instrumental to the delivery of cholesterol to distal
axons for synaptogenesis, dendritogenesis, axonal guidance, sig-
naling, and release of synaptic vesicles in neurotransmission (de
Chaves et al., 1997; Posse De Chaves et al., 2000; Mauch et al.,
2001; Hering et al., 2003; Goritz et al., 2005). The concomitant
neuronal uptake of ApoE and cholesterol present in spherical
and discoidal high-density lipoprotein (HDL)-like particles is
via a family of low-density lipoprotein receptors, which include
low-density lipoprotein receptor (LDLR), LDLR-related protein 1
(LRP1), and ApoE receptor 2 (ApoER2). The structural confor-
mation of ApoE, as dictated by its isoform and lipidation status,
determines its binding affinity to LDL receptors (Hatters et al.,
2006). Experimental evidence revealed that a positively charged
amino acid at position 158 in ApoE is essential for effective bind-
ing to LDL receptors (Innerarity et al., 1984; Dong et al., 1996). It
is noteworthy that ApoE2 is defective in binding to LDLR, which
is due to reduced positive electrostatic potential with a cysteine
at this position (Weisgraber et al., 1982; Lund-Katz et al., 2001),
yet it is the most protective ApoE isoform against AD. ApoE3 and
ApoE4 bind to LDLR with similar affinity. Furthermore, lipida-
tion of ApoE is essential for binding to LDL receptors, and an
in vitro lipid binding experiment demonstrated that ApoE4 has
the highest lipid binding affinity, although all isoforms have a
similar lipid binding capacity (Saito et al., 2003).
In addition to its role in neuronal cholesterol delivery, ApoE
is essential also to cholesterol efflux from neurons and astro-
cytes. In this pathway, ApoE functions as an acceptor of cellular
cholesterol and other lipids from cell surface ATP-binding cas-
sette transporters such as ABCA1 and ABCG1 (Kim et al., 2007,
2008; Minagawa et al., 2009). This process of ApoE lipidation
then increases ApoE affinity for LDL receptors for delivery of
cholesterol to neurons. The effectiveness of ApoE as a choles-
terol acceptor is isoform-specific. In vitro experimental evidence
showed that highest cholesterol efflux activity is achieved in both
neuronal and astrocyte cultures in the presence of exogenous
ApoE2 (Michikawa et al., 2000). Therefore, the neuroprotective
capacity of ApoE2 may be partially explained by its proficiency in
facilitating cellular cholesterol efflux, despite being ineffective in
cholesterol delivery due to inefficient binding to LDLR.
INTRANEURONAL CHOLESTEROL TRANSPORT
The intracellular fate of ApoE-bound cholesterol in neurons
is believed to follow that of the classical clathrin-dependent
receptor-mediated endocytic pathway [reviewed in Goldstein and
Brown (2009)]. HDL-like particles containing cholesterol-bound
ApoE/LDLR complex associate with the clathrin-coated vesicles,
which initially fuse with the sorting endosomes, where the com-
plex dissociates and LDLR is then either recycled back to the cell
surface or delivered to lysosomes for degradation. HDL-like par-
ticles are further transported to the late-endosomes/lysosomes,
where the acidic environment of these compartments pro-
motes the dissociation of the HDL-like particles, liberating
ApoE and cholesterol. The subsequent mobilization of choles-
terol from late-endosomes/lysosomes involves NPC1 and NPC2
proteins (Vanier, 2010). Fibroblast cells extracted from NP-C
patients with a deficiency in either NPC1 and/or NPC2 pro-
teins show an entrapment of unesterified cholesterol in late-
endosomes/lysosomes (Pentchev et al., 1985; Kruth et al., 1986).
This abnormal cholesterol accumulating phenotype is present
also in both NP-C human and mouse model brains (Karten
et al., 2002; Distl et al., 2003; Treiber-Held et al., 2003). More
recently, in vitro experiments that demonstrate direct binding
and interactions between NPC1, NPC2, and cholesterol pro-
vided further support for a critical role for NPC1 and NPC2
in intracellular cholesterol transport (Infante et al., 2008a,b,c;
Kwon et al., 2009; Wang et al., 2010). It has been postu-
lated that NPC1 and NPC2 mediated cholesterol egress from
late-endosomes/lysosomes can be diverted to either the ER for
esterification by acetyl-coenzyme A:cholesterol acetyltransferase
(ACAT) for storage of the excess in cytosolic lipid droplets, or
to the plasma membrane for export by cholesterol transporters
(e.g., ABCA1 and ABCG1). Genetic defects in ABCA1 causes
Tangier disease (Kolovou et al., 2006), which exhibits a cholesterol
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accumulating phenotype similar to that found in NP-C and is
characterized by HDL-deficiency. There are limited reports on
the effects of ABCA1 mutations in the central nervous system
(Pietrini et al., 1990; Negi et al., 2013), with premature atheroscle-
rosis and neuropathy being the best documented symptoms of
Tangier disease.
BRAIN CHOLESTEROL EXPORT
Cholesterol cannot be degraded. At present, there are two known
pathways for brain cholesterol elimination. One route of brain
cholesterol removal is via ApoE secretion into the CSF and export
from the brain at a rate of 1–2mg/day by an unknown mecha-
nism (Pitas et al., 1987b; Xie et al., 2003). Cholesterol removed
by this pathway is believed to originate primarily from glial cells.
Alternatively, the main route of brain cholesterol elimination,
primarily of neuronal origin, is via conversion of cholesterol to
BBB-permeable oxidized cholesterol species (oxysterols). The pri-
mary brain oxysterol species is 24S-hydroxycholesterol (24OHC),
the product of 24S-hydroxylase (CYP46) catalyzed addition of
a hydroxyl group to the 24-position of cholesterol (Lutjohann
et al., 1996; Björkhem et al., 1997, 1998; Lund et al., 1999,
2003; Lutjohann and von Bergmann, 2003). The rate of 24OHC
movement from the brain into the circulation is estimated at
6–7mg/day (Lutjohann et al., 1996; Björkhem et al., 1998). A
corresponding rate of uptake in the liver has led to the hypoth-
esis that 24OHC is an exclusive product of the brain, and its
concentration in the circulation is reflective of brain cholesterol
metabolism (Bretillon et al., 2000; Lutjohann and von Bergmann,
2003). In the liver, 24OHC is further converted to bile acids for
excretion from the body (Björkhem et al., 2001). By analogy with
24OHC penetration of the BBB, 27-hydroxycholesterol (27OHC)
produced by peripheral cells can enter the brain from circulation
at a rate of 5mg/day (Heverin et al., 2005). There are no known
oxysterol transporters, and the transfer of oxysterols across cell
membranes is hypothesized to be driven by the concentration
gradient (Björkhem et al., 2009).
Oxysterols play an important part in regulation of whole
body cholesterol homeostasis. They can activate liver X receptors
(LXRs), LXRα, and LXRβ [reviewed in Björkhem (2013)], which
regulate a number of genes in the cholesterol metabolic pathway
including ABCA1, ABCG1, SREBP-1, and ApoE. Interestingly,
cultured glial cells respond to a greater extent to LXR agonist
stimulation of LXR target gene expression and cholesterol efflux
compared with cultured neuronal cells (Whitney et al., 2002).
Thus, LXR and 24OHC are connected in a feedback mechanism
to maintain a net cholesterol export, where an increased export of
neuronal cholesterol in the form of 24OHC activates cholesterol
export from glial cells for delivery to neurons (Pfrieger, 2003).
In addition to LXRs, other members of the same nuclear recep-
tor family that also regulate genes in the cholesterol metabolic
pathway include peroxisome proliferator-activated receptor γ
(PPARγ) and retinoid X receptors (RXRs).
CROSSTALK BETWEEN COPPER AND CHOLESTEROL
METABOLISM
The interaction between copper and cholesterol metabolic path-
ways in the brain is an area of limited research. The majority
of current investigations center mainly on peripheral changes.
Dietary manipulations in animal studies revealed an inverse
relationship between copper and cholesterol in their respective
peripheral concentrations. Rats and rabbits fed a high choles-
terol diet have decreased hepatic copper concentration compared
with animals on a control diet (Klevay, 1988; de Wolf et al.,
2003a,b). Increased bilirubin secretion has been proposed as the
potential mechanism underlying cholesterol induced hepatic cop-
per reduction (de Wolf et al., 2003b). However, in the Watanabe
heritable hyperlipidemic rabbits, an animal model for familial
hypercholesterolemia, there is no inverse correlation with copper,
which is significantly elevated (Allain et al., 1989). These obser-
vations indicate that dietary and genetic changes in cholesterol
have differential effects on copper metabolism. It is conceivable
that dietary cholesterol alters cholesterol homeostasis in a man-
ner that affects cellular membrane fluidity and dynamic, which
impacts on the structure and function of membrane-localized
copper transporters. For example, pharmacological depletion of
cellular cholesterol levels using the cholesterol sequestering agent
methyl-β-cyclodextrin (MβCD) resulted in a shift of the copper
transporter CTR1 in HeLa cells from a perinuclear localization
to a more diffused vesicular and plasma membrane distribution
(Klomp et al., 2002), and thus cause a change in cellular copper
balance. However, the exact mechanism underlying the impact of
altered cholesterol metabolism on copper homeostasis remains to
be elucidated.
In animals fed a copper deficient diet, peripheral cholesterol
synthesis is stimulated via up-regulation of HMG-CoA reduc-
tase and SREBP-1, and they develop hypercholesterolemia (Carr
and Lei, 1989; Yount et al., 1990; Lei, 1991; al-Othman et al.,
1994; Tang et al., 2000). In contrast, brain cholesterol synthe-
sis and myelination is sensitive to dietary and genetic copper
deficiencies (Figure 1). Mice given dietary supplement of cupri-
zone, a copper chelator, showed a significant down-regulation of
HMG-CoA reductase mRNA expression and cholesterol synthe-
sis, and consequently, severe demyelination, affecting particularly
the corpus callosum (Jurevics et al., 2001, 2002). These effects are
reversible by removal of cuprizone from the diet. Similarly, pro-
found brain copper deficiency inMenkes disease, due to absent or
defective activity of the ATP7A copper transporter, is associated
also with significantly reduced brain cholesterol and extensive
myelin defects (Hara and Taketomi, 1986). Conversely, copper
overload in the Atp7b−/− mouse model of Wilson disease is
associated also with reduced brain and hepatic concentrations
of cholesterol, lathosterol, desmosterol, 8-hydrocholesterol, and
7-dehydrocholesterol (Sauer et al., 2011). These changes are con-
sistent with down-regulation of cholesterogenic gene expression
and reduction in nuclear receptor transcription factors farnesoid
X receptor (FXR) and glucocorticoid receptor (GR) in the liver
of the same animal model (Huster et al., 2007; Wilmarth et al.,
2012). However, the decrease in serum cholesterol observed in
animal models of Wilson disease is not recapitulated in a study
of human Wilson disease patients (Seessle et al., 2011). Also
inconsistent with in vivo animal studies, a microarray analysis of
in vitro human macrophage culture treated with copper found
up-regulation of seven cholesterolgenic genes, which include
HMG-CoA synthase, squalene synthase, and LDLR (Svensson
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FIGURE 1 | Schematic diagram of the effects of dietary and genetic
copper manipulation on cholesterol levels, based on available data
from animal models. Light blue and dark blue arrows represent pathways
associated with copper deficiency and overload conditions, respectively.
Black arrows denote either increased (↑) or decreased (↓)
3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase expression
or cholesterol levels as a consequence of altered copper levels.
et al., 2003). These observations suggest that there may be
tissue- and species-specific differences in cholesterol metabolism
in response to copper. There is clearly a close and complex rela-
tionship between the copper and cholesterol metabolic pathways.
The full impact of altered copper homeostasis with regard to
cholesterol metabolism remains to be fully explored.
DISINTEGRATION OF COPPER AND CHOLESTEROL
METABOLISM IN ALZHEIMER’S DISEASE
Late-onset AD is a complex multifactorial disorder, and to date,
the exact etiology remains elusive. There are largely indepen-
dent bodies of literature documenting the disruption to copper
and cholesterol homeostasis and how they may contribute to the
development and progression of AD.Observations from epidemi-
ological studies of changes in plasma copper and cholesterol as
discriminating markers for AD have been inconsistent (Jarvik
et al., 1995; Notkola et al., 1998; Gonzalez et al., 1999; Squitti
et al., 2002, 2003, 2005, 2006, 2007; Reitz et al., 2004, 2008;
Mielke et al., 2005; Pajonk et al., 2005; Kessler et al., 2006;
Kivipelto and Solomon, 2006; Solomon et al., 2007; Zambon
et al., 2010; Rembach et al., 2013). The inherent genetic and
environmental heterogeneity in different human populations
may contribute to the ambiguous observations. Nevertheless,
epidemiological and animal studies found that a high fat diet
is associated with cognitive decline and increased risk for AD
(Morris et al., 2003; Sparks, 2008). High copper consumption
with a high saturated and trans fat diet further accelerates the
cognitive decline (Morris et al., 2006). The latter study sug-
gests that the association is independent of dietary cholesterol,
zinc and iron; but this study did not account for potential
effects due to stimulation of endogenous cholesterol synthesis.
An AD cholesterol-lowering treatment trial involving atorvas-
tatin reported an increase in plasma CP as a measure of copper
(Sparks et al., 2005), further suggesting an interaction between
copper and cholesterol homeostasis in AD. Collectively, these
studies, which mostly document peripheral copper and choles-
terol changes, indicate a synergistic failure of copper and choles-
terol metabolic pathways that contributes to cognitive decline and
pathogenesis of AD.
INTERACTIONS OF COPPER AND CHOLESTEROLWITH APP AND Aβ
Amyloid plaques that are characteristic of AD brains contain
high concentrations of the Aβ peptide, cholesterol and transi-
tion metals (copper, iron and zinc) (Glenner and Wong, 1984;
Masters et al., 1985; Lovell et al., 1998; Dong et al., 2003; Miller
et al., 2006; Panchal et al., 2010). Central to the formation of
amyloid plaques is the processing of APP, a glycosylated type
I transmembrane protein. There are two alternative APP pro-
cessing pathways, commonly referred to as the amyloidogenic
or non-amyloidogenic pathway (Thinakaran and Koo, 2008).
The release of Aβ by sequential β- and γ-secretase cleavage
of APP in the amyloidogenic pathway is most relevant to AD
pathogenesis. Conversely, non-amyloidogenic processing of APP
involves sequential α- and γ-secretase cleavages to release a non-
neurotoxic p3 peptide. Cleavage by γ-secretase in both pathways
liberates a common C-terminal fragment known as APP intracel-
lular domain (AICD), which can translocate to the nucleus and
function as a transcription factor.
Cholesterol is a widely recognized key regulator of APP
processing. Amyloidogenic processing of APP preferentially
occurs in cholesterol- and glycosphingolipid (GSL)-rich lipid
raft microdomains (Simons and Ikonen, 1997; Ehehalt et al.,
2003; Kawarabayashi et al., 2004; Vetrivel et al., 2004; Hooper,
2005; Cordy et al., 2006; Cheng et al., 2007; Schneider et al.,
2008; Thinakaran and Koo, 2008; Hung et al., 2009; Vetrivel
and Thinakaran, 2010). APP interactions at the cell surface
with flotillin-2, a lipid raft protein (Schneider et al., 2008),
and cholesterol via its C-terminal domain (Beel et al., 2008)
are critical to its partitioning into lipid rafts and trafficking
(Figure 2). Internalization of APP from the cell surface to BACE1
(β-secretase)-rich acidic endosomes is cholesterol-sensitive and
pro-amyloidogenic (Refolo et al., 1995; Vassar et al., 1999;
Schneider et al., 2008; Cossec et al., 2010; Marquer et al., 2011).
Alternatively, cholesterol depletion triggers destabilization of lipid
rafts, decreased APP internalization and lipid raft localization,
inhibition of β- and γ-secretase activities, and reduced Aβ pro-
duction (Simons et al., 1998; Fassbender et al., 2001; Riddell
et al., 2001; Ehehalt et al., 2003; Vetrivel et al., 2004, 2005;
Urano et al., 2005; Cordy et al., 2006; Schneider et al., 2008;
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FIGURE 2 | Schematic models illustrating the interactions between
copper, cholesterol and APP metabolism. (A) Under normal and/or
elevated cellular copper conditions, there is an increased translocation
of APP and ATP7A from the trans-Golgi network (TGN) to the plasma
membrane (PM), where they participate in copper efflux. The majority
of the APP molecules undergo non-amyloidogenic processing via
α-secretase cleavage at the cell surface in non-lipid raft membrane
domains, which produces a non-toxic p3 fragment. It is expected that
a basal level of β-cleavage of APP occurs in cholesterol-rich lipid raft
domains of acidic endosomes enriched in BACE1, the β-secretase. Aβ40,
the product of the sequential cleavage of APP by β- and γ-secretases,
is proposed to inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase activity as a part of a feedback mechanism by which
cholesterol-dependent regulation of APP occurs (Grimm et al., 2005).
(B) In contrast, under conditions of copper deficiency, such as that
present in Alzheimer’s disease (AD), there may be increased APP
interactions with flotillin-2 at the PM, increased APP partitioning into
lipid rafts, enhanced internalization of APP to BACE1-rich endosomes for
amyloidogenic processing and generation of Aβ in lipid rafts. The
combination of Aβ, cholesterol and copper in lipid rafts fosters a
favorable environment for the formation of redox-active Aβ:Cu2+
complexes, which can catalytically oxidize cholesterol, and may potentiate
neurotoxicity by generating H2O2 and toxic oxysterol species. Although
there may be an increased production of Aβ, the formation of Aβ:Cu2+
oligomers may result in reduced availability of Aβ to inhibit HMG-CoA
reductase activity and consequently, increased cholesterol synthesis.
Won et al., 2008; Cossec et al., 2010; Marquer et al., 2011).
Two common agents used to deplete cholesterol are methyl-β-
cyclodextrin (MβCD) and statins. MβCD extracts cholesterol
from cellular membranes. Statins are inhibitors of HMG-CoA
reductase, thereby achieving cholesterol reduction by interfering
with endogenous cholesterol synthesis via the mevalonate path-
way. Given the pro-amyloidogenic nature of cholesterol, it has
been considered as a potential therapeutic target for treatment
of AD. A number of clinical trials have investigated the benefi-
cial effects of statins [reviewed in Shepardson et al. (2011a,b)].
The outcomes are variable due to the pleiotropic nature of statins,
which differ in their BBB permeability and additional off-target
effects on the isoprenylation pathway.
Copper also modulates APP processing (Borchardt et al., 1999;
Cater et al., 2008; Hung et al., 2009). Conditions of copper defi-
ciency, such as that found in brain tissues from AD patients
and transgenic mouse models promote amyloidogenic process-
ing of APP (Deibel et al., 1996; Maynard et al., 2002, 2006; Bayer
et al., 2003; Phinney et al., 2003; Magaki et al., 2007; Cater et al.,
2008) in cholesterol-rich lipid rafts (Hung et al., 2009) (Figure 2).
Conversely, increasing cellular copper levels via dietary, pharma-
cological or genetic manipulations favors the non-amyloidogenic
processing of APP and inhibits Aβ production (Borchardt et al.,
1999; Cherny et al., 2001; Bayer et al., 2003; Phinney et al., 2003;
White et al., 2006; Adlard et al., 2008; Cater et al., 2008; Donnelly
et al., 2008; Hung et al., 2009). Analogous to cholesterol depletion,
increased cellular copper reduces the association of flotillin-2
with lipid rafts (Hung et al., 2009), retards APP internalization
and attenuates Aβ production (Hung et al., 2009; Acevedo et al.,
2011). It can be envisaged that the copper-dependent effect on
APP processing may be achieved via regulation of cholesterol
synthesis (see Section Crosstalk between copper and cholesterol
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metabolism). The alteration in copper-induced APP redistri-
bution and processing may stimulate a compensatory response
in the up-regulation of APP mRNA and protein expression
(Armendariz et al., 2004; Bellingham et al., 2004b; Cater et al.,
2008).
In a reciprocal manner, APP participates in the regulation
of copper and cholesterol metabolism. A dual mechanism is
involved in APP regulation of cholesterol metabolism. The bind-
ing of cholesterol to APP C-terminal domain promotes its
amyloidogenic processing, and the release of Aβ and AICD.
Experimental evidence demonstrates that Aβ40 inhibits the activ-
ity of HMG-CoA reductase, the rate limiting enzyme in the
cholesterol synthesis pathway, so that APP deficiency results
in cholesterol accumulation (Grimm et al., 2005). An addi-
tional mechanism of cellular cholesterol reduction is achieved
by translocation of AICD into the nucleus, where it down-
regulates LRP1 expression by transcription suppression (Liu et al.,
2007). Thus, APP is proposed as a cholesterol sensor to con-
trol cellular cholesterol levels and is own processing (Beel et al.,
2008). Additionally, APP is proposed to regulate copper efflux.
This hypothesis evolved from evidence that APP expression
inversely correlates with copper levels in cell and animal mod-
els (White et al., 1999b,c; Maynard et al., 2002; Phinney et al.,
2003; Bellingham et al., 2004a). Over-expression of APP or its
C-terminal domain (C100) that contains the Aβ sequence is asso-
ciated with copper deficiency in transgenic mouse models of AD
(Maynard et al., 2002; Bayer et al., 2003; Phinney et al., 2003).
Conversely, APP deficiency causes copper accumulation (White
et al., 1999c; Bellingham et al., 2004a). The concomitant rise
in copper and cholesterol in APP knockout animals suggests an
interaction between these pathways that becomes uncoupled in
its absence.
Oxidative stress is a pathological feature of AD. It is notewor-
thy that the inverse nature of copper distribution to cholesterol-
rich lipid rafts relative to cellular copper concentrations fosters
an environment conducive to oxidative stress (Hung et al., 2009)
(Figure 2). Lipid raft co-enrichment of Aβ and copper favors
the formation of redox-active Aβ:Cu2+ complexes that catalyt-
ically generate H2O2 via reduction of Cu2+ to Cu+ (Atwood
et al., 1998, 2004; Huang et al., 1999; Cuajungco et al., 2000;
Hung et al., 2009). Cholesterol and long-chain fatty acids in lipid
rafts are obvious electron donors that participate in this reac-
tion (Opazo et al., 2002; Haeffner et al., 2005; Murray et al.,
2005, 2007), and consequently are converted to oxysterols and
lipid peroxidation products, such as 7β-hydroxycholesterol and
4-hydroxynonenal (HNE), which are present in abundance in
the brains of human AD cases and mouse models (Opazo et al.,
2002; Murray et al., 2005, 2007; Nelson and Alkon, 2005; Puglielli
et al., 2005; Yoshimoto et al., 2005; Jiang et al., 2007). A neuro-
toxic vicious cycle then ensues, where oxidatively modified lipids
stimulate the formation of Aβ oligomers complexed with copper
and enter a continual pathological redox cycle oxidizing choles-
terol and other membrane lipids (Koppaka and Axelsen, 2000;
Barnham et al., 2003; Ciccotosto et al., 2004; Murray et al., 2005,
2007; Tickler et al., 2005; Liu et al., 2008). Furthermore, in vitro,
oligomers of Aβ:Cu2+ can penetrate artificial membrane systems
to form cation channels (Bhatia et al., 2000; Curtain et al., 2001,
2003; Lin et al., 2001). Collectively, these observations suggest
that a combination of copper, soluble Aβ oligomers and choles-
terol may potentiate neurotoxicity via lipid oxidation and altered
membrane integrity.
Sporadic AD is often simulated by cholesterol feeding of
animal models (rabbits, beagles, and mice) to induce AD-like
pathologies and cognitive deficits (Ghribi et al., 2006; Woodruff-
Pak et al., 2007; Ghribi, 2008; Sparks, 2008; Lu et al., 2009, 2006;
Sparks et al., 2011). In rabbit brains, amyloid plaque-like struc-
tures are detected in the hippocampus and temporal lobe, similar
to that in human AD brains (Sparks and Schreurs, 2003; Sparks,
2004; Sparks et al., 2006; Woodruff-Pak et al., 2007). Additional
consumption of trace amounts of copper (0.12 ppm) in drink-
ing water, but not zinc or aluminum, accelerated the cognitive
decline with exacerbated amyloid pathology in cholesterol-fed
rabbits suggestive of an interaction between dietary cholesterol
and copper in this event (Sparks et al., 2006). In contrast, a nor-
mal diet with copper only treatment had no significant effect on
amyloid pathology and cognition (Sparks and Schreurs, 2003; Lu
et al., 2006). However, more recent studies showed conflicting
data that copper treatment alone at a higher concentration of
0.24 ppm resulted in increased Aβ-positive neurons in the rab-
bit model (Deci et al., 2012); and chronic treatment of rodent
models at a high dosage (250 ppm) also enhanced the amyloid
pathology (Kitazawa et al., 2009; Mao et al., 2012). The impact
of higher copper intake on cholesterol homeostasis in these stud-
ies is unclear. Potential mechanisms of dietary cholesterol in
causing brain Aβ accumulation include increased circulating and
brain concentrations of 27-OHC, and up-regulation of APP and
BACE1 expression (Ghribi, 2008; Prasanthi et al., 2009; Shafaati
et al., 2011; Popp et al., 2012). Copper may contribute to aug-
mentation of dietary cholesterol-induced amyloid pathology and
neurotoxicity by further up-regulating APP and BACE1 expres-
sion, increasing oxidative stress and activation of inflammatory
pathways (Lu et al., 2006, 2009; Lin et al., 2008). An alternative
hypothesis for copper-induced aggravation of amyloid pathol-
ogy in cholesterol-fed animals is by impeding the clearance of
Aβ complexed to ApoE-cholesterol from the brain for removal
from the body by the liver (Sparks, 2007). However, the exact
biochemical mechanism remains to be elucidated.
LINK BETWEEN COPPER AND ApoE
There is an emerging literature linking the main extracellular
cholesterol transporter ApoE and copper, alluding to a poten-
tial protective role for ApoE against copper-mediated toxicity
and/or copper regulation. The antioxidant activity of ApoE is
isoform-specific, in the order of E2>E3>E4, with ApoE2 demon-
strating a >2-fold higher activity relative to ApoE4 (Miyata
and Smith, 1996). The same study showed that ApoE binds
metals including copper, zinc and iron, with highest affinity
for copper, and it inhibits copper-mediated lipoprotein oxi-
dation. The authors proposed that copper sequestration may
account for the antioxidant activity of ApoE. Moreover, copper-
induced Aβ accumulation and aggregation is most pronounced
in the presence of ApoE4 compared with ApoE2 and ApoE3
(Moir et al., 1999). Hence, the ability of ApoE to bind to cop-
per with high affinity is a potential mechanism for mitigating
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copper-mediated lipoprotein oxidation and copper-induced Aβ
aggregation (Miyata and Smith, 1996; Moir et al., 1999). The
precise ApoE copper-binding mechanism is unknown. Potential
sites that may coordinate copper include the methionine residues
within the N-terminal four-helix bundle (Miyata and Smith,
1996). The cysteines of ApoE2 at amino acid positions 112 and
158 have the potential to bind copper, while ApoE4, which lacks
the cysteine residues, is proposed to have a reduced copper bind-
ing capacity and thus, decreased ability to clear Aβ from the brain
(Brewer, 2009). However, this may not be feasible based on apoE
structural studies [reviewed in Hatters et al. (2006)], which sug-
gest that these cysteine residues are positioned in an opposing
orientation.
An ApoE-copper connection was further supported by the
finding that inWilson disease patients with the commonH1069Q
mutation in the copper transporter ATP7B, an earlier onset
of symptoms is associated with the APOE-ε4 genotype (Litwin
et al., 2012). In comparison, APOE-ε3 genotype is associated
with a significant delay in the onset of Wilson disease symp-
toms (Schiefermeier et al., 2000; Wang et al., 2003). The authors
proposed that ApoE4 is less effective than ApoE2/ApoE3 as an
antioxidant so that ApoE4 patients are more susceptible to copper
toxicity. These studies further suggest a role for ApoE in copper
regulation and in influencing Wilson disease phenotypes, but the
exact mechanism remains unclear.
It is noteworthy that ApoJ also interacts with the ATP7A and
ATP7B copper transporters that are defective in Menkes and
Wilson diseases, respectively (Materia et al., 2011, 2012). ApoJ
facilitates their degradation and thus can influence cellular cop-
per levels. However, the integration of these apolipoproteins’ lipid
transport and Aβ clearance activities with their role in copper
regulation remains to be further clarified.
COPPER, CHOLESTEROL, AND TAU
NFTs, the other distinguishing pathological hallmark of AD,
are mainly formed from aggregates of hyperphosphorylated tau
protein [reviewed in Avila et al. (2004), Morris et al. (2011),
Spires-Jones et al. (2009)]. Tau is best characterized for its role
in polymerization and stabilization of neuronal microtubules,
and regulation of axonal transport of synaptic vesicles in neu-
rotransmission (Thies and Mandelkow, 2007; Dixit et al., 2008).
However, it is increasingly recognized as a multi-functional pro-
tein. Recent findings report the release of tau with synaptic
vesicles as a part of neurotransmission (Pooler et al., 2013)
and it has been ascribed a regulatory role in neuronal signaling
pathways (Ittner et al., 2010, 2011). Phosphorylation of tau is
well-established as a modification that regulates its activity, par-
ticularly with respect to its interactions with microtubules. An
imbalance of tau interacting kinase and phosphatase activities is
believed to contribute to the genesis of hyperphosphorylated tau
abundant in NFTs.
Tau has a peripheral membrane association via its N-terminal
projection domain, implicating a role for tau in neurite
outgrowth (Brandt et al., 1995). However, there is limited infor-
mation regarding a direct interaction between tau and cholesterol
or other lipids. Lipid raft studies have revealed an AD- and age-
dependent enrichment of tau phosphorylated at NFT-associated
epitopes in brain tissues from human AD cases and the Tg2576
mouse model (Kawarabayashi et al., 2004). Indeed, there is a co-
localization of cholesterol andNFTs in the same neuronal popula-
tions in AD and NP-C brains (Distl et al., 2001). Pharmacological
cholesterol depletion by statin-mediated inhibition of cholesterol
synthesis resulted in enhanced tau phosphorylation at NFT-
associated epitopes (Fan et al., 2001). These data are suggestive of
a role for cholesterol in tau phosphorylation and development of
NFTs, although themechanism involved remains to be elucidated.
Literature on the interaction between copper and tau is also
limited. The promoter of the tau (MAPT) gene has the poten-
tial to be regulated by Sp1, a copper-responsive transcription
factor (Heicklen-Klein and Ginzburg, 2000; Song et al., 2008;
Bellingham et al., 2009). Over-expression of tau inhibits traf-
ficking of APP to the cells surface (Stamer et al., 2002); and
ATP7A traffics to the cell surface along the microtubule net-
work (Cobbold et al., 2004). Therefore, it is plausible that
copper-regulated tau expression may be a regulatory mecha-
nism to control copper-responsive trafficking of APP and ATP7A
(Stamer et al., 2002; Cobbold et al., 2004; Hung et al., 2009;
Acevedo et al., 2011). The functional implications of this regu-
latory control include NMDA receptor-mediated excitotoxicity,
ATP7A-mediated synaptic release of copper andAPPmetabolism.
Copper is associated with NFTs (Sayre et al., 2000). In vitro
experiments indicate that adventitious binding of copper to tau
is redox-competent and contributes to neuronal oxidative stress
through the generation of hydrogen peroxide. Detailed structural
and biophysical characterization of the longest human tau iso-
form established that tau binds to one Cu2+ ion per monomer
under mild acidic conditions with high affinity (Kd = 0.5μM)
(Soragni et al., 2008). Copper coordination involves the cysteine
residues 291 and 322 within the microtubule-binding domain.
It is notable that evidence from in vitro experiments suggests
that copper-mediated tau aggregation is phosphorylation inde-
pendent; but the manner in which copper may catalyze tau
aggregation in vivo is unknown.
The effects of copper on tau pathology in vivo in AD mod-
els also reveal conflicting results. Copper modulation by treat-
ing a double transgenic AD mouse model with CuII(gtsm),
a bis(thiosemicarbazone) or PBT2, a copper/zinc ionophore,
improved tau phosphorylation, Aβ oligomerization and cog-
nition (Adlard et al., 2008; Crouch et al., 2009). However,
chronic administration of CuSO4 to a triple transgenic ADmouse
model caused an increase in cdk5/p25 phosphorylated tau species
(Kitazawa et al., 2009). These apparent discrepancies remain to be
resolved.
In general, studies that investigate the interaction between cop-
per, cholesterol and tau are lacking. In cholesterol-fed rabbits,
copper appears to ameliorate tau pathology in the hippocampus
and frontal cortex of cholesterol-fed rabbits, but induces a con-
comitant rise in plasma tau concentration (Sparks et al., 2011).
The mechanism that underlies this observation awaits further
studies. Interestingly, in the cholesterol-fed rabbits, the apparent
normalization effect of copper on brain tau pathology opposes
the negative impact of copper on the amyloid pathology. There
is no reasonable explanation for this apparent contradiction at
present.
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CONCLUSIONS
AD is a complex and multifactorial neurodegenerative disor-
der, and failures in many biochemical pathways are implicated
in the pathogenesis of sporadic late-onset AD. Disruption of
copper and cholesterol homeostasis are two major pathological
features of AD, but whether abnormalities in copper and choles-
terol are a cause or consequence of the disease process is not
clear. The finding of impaired copper and cholesterol metabolism
in other neurodegenerative diseases such as PD and NP-C high-
lights the possibility that there are fundamental mechanisms
linking the biochemistry of these essential cellular constituents.
This review has highlighted the essential requirements for copper
and cholesterol for normal brain functions, and has summarized
the growing body of evidence documenting the close and com-
plex relationship between copper and cholesterol metabolism.
Clearly disturbance to one is associated with dysregulation of the
other. The complexity is further enhanced by the interactions
of copper and cholesterol with key proteins that are dysregu-
lated or malfunction in AD such as, APP, Aβ and tau; and the
heterogeneity of genetic and environmental influences between
individuals and populations. For example, there is an intimate
interaction between copper and cholesterol in APP metabolism
that may explain some of the neurodegeneration evident in AD.
Key issues that could be addressed to provide further insight
are: (1) the relationship between copper, cholesterol and tau; (2)
whether the major risk associated factors ApoE and ApoJ are asso-
ciated with copper in vivo and whether copper is necessary for
their function; (3) whether copper is associated with HDL-like
particles containing cholesterol-bound ApoE and if so, the func-
tional significance of this in both copper and cholesterol transport
and AD. Further research is required for an integrated under-
standing of the molecular mechanisms connecting copper and
cholesterol homeostasis with various players in AD, and how their
disintegration may contribute to the development and progres-
sion of AD. Such knowledge is critical to the design of effective
disease-modifying therapeutic targets.
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